Shares of once high-flying biotech company Ocugen (NASDAQ:OCGN) are seeing some selling pressure again today. At the time of writing, OCGN stock is down over 9% on a business update provided by the company.Ocugen noted that Phase 3 trials of its OCU400 gene therapy drug are expected to commence in April, and other positive designation-related news was put forward. However, in this release, the company also revealed it would need to restate some of its financial statements.The company noted that errors were ...